Insilico Medicine Raises $110M Series E for AI Drug Discovery Innovation

CAMBRIDGE, Mass., March 13, 2025 — Insilico Medicine, a clinical-stage company specializing in AI-driven drug discovery, has announced the successful completion of its Series E financing round, raising $110 million. This round was spearheaded by Value Partners Group, a prominent private equity fund, with significant backing from new investors focused on industry and technology, as well as robust support from existing global investors.

The funds acquired through this financing will be utilized to enhance Insilico's drug pipeline and AI platform. Part of the resources will be allocated to refining AI models and algorithms, along with developments in its advanced automated laboratory designed to streamline research processes. Additionally, Insilico aims to progress the clinical trials of its leading candidate for treating idiopathic pulmonary fibrosis and accelerate research and development of other drugs, both self-developed and co-developed, to foster innovation in healthcare.

Dr. Chuen Yan Leung, Partner at Value Partners, expressed enthusiasm about the collaboration with Insilico Medicine, stating, “We are excited to partner with Insilico Medicine in its mission to transform drug discovery with AI and automation. With a proven track record and leadership in AI-driven drug development, Insilico is at the forefront of transforming the industry. We believe that Insilico's advancements will accelerate the development of life-saving therapies and redefine the future of biopharmaceutical R&D.”

Insilico Medicine CEO, Alex Zhavoronkov, PhD, emphasized the significance of the financing round, saying, “We are thrilled to announce our $110 million Series E financing—a key milestone that reflects our unwavering commitment to transforming healthcare and the strong confidence of our investors. This round, led by Value Partners and anchored by industry-focused investors, was heavily oversubscribed, drawing exceptional interest from prominent investors.”

Since its prior financing, Insilico has achieved remarkable progress in advancing its AI platform and drug discovery pipeline. The company’s proprietary AI-driven platform has demonstrated its ability to significantly cut costs and increase efficiency during the early stages of drug discovery. Insilico’s integration of advanced AI and automation technologies has reduced the average time to preclinical candidate nomination to just 12-18 months, compared to traditional methods that typically take 2.5-4 years. This approach allows synthesis and testing of only 60-200 molecules per program.

Insilico's Pharma.AI platform, which undergoes major updates twice annually, provides comprehensive solutions spanning biology, generative chemistry, clinical medicine, and scientific research. Enhancements to Pharma.AI include innovative engines powered by large language models (LLMs), such as Nach01 for natural and chemical languages, and Dora, a generative research assistant. Recently, Insilico introduced a bipedal humanoid AI Scientist within Life Star1, its fully robotic lab connected to Pharma.AI, aimed at optimizing and automating research workflows.

To date, Insilico has created a wholly-owned drug discovery portfolio consisting of 30 assets, with 10 receiving Investigational New Drug (IND) clearance. The most advanced candidate, Rentosertib, intended for idiopathic pulmonary fibrosis treatment, has shown promising results in clinical trials. A Phase IIa trial indicated Rentosertib’s favorable safety and tolerability at all dose levels, with a dose-dependent response in forced vital capacity after 12 weeks.

Insilico also generates sustainable revenue through its out-licensing business model, having secured agreements valued at over $2.1 billion with companies like Fosun Pharma, Exelixis, and Menarini. Collaborations with partners like Sanofi, Saudi Aramco, and Therasid Bioscience have accumulated a value exceeding $1.4 billion, reaching milestones that result in payments contributing to Insilico's financial growth.

With the completion of its Series E financing, Insilico is positioned to further advance AI-powered biopharmaceutical research and development, strengthen industry collaborations, and apply its cutting-edge AI platform across diverse life sciences scenarios.